JPMORGAN CHASE & CO - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 77 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$837,184
-42.9%
709,478
-31.8%
0.00%
Q2 2023$1,467,086
-12.0%
1,040,487
-6.4%
0.00%
Q1 2023$1,668,000
+130826.2%
1,112,111
+2.2%
0.00%
Q4 2022$1,274
-99.9%
1,088,579
+3.8%
0.00%
Q3 2022$1,185,000
-40.3%
1,049,051
-16.5%
0.00%
Q2 2022$1,986,000
-30.3%
1,256,932
-32.0%
0.00%
Q1 2022$2,849,000
-9.4%
1,849,662
+44.1%
0.00%
Q4 2021$3,145,000
-43.7%
1,283,277
-42.1%
0.00%
-100.0%
Q3 2021$5,584,000
+0.4%
2,215,792
+13.5%
0.00%0.0%
Q2 2021$5,564,0001,952,108
+2674020.5%
0.00%
Q1 2021$0
-100.0%
73
-96.8%
0.00%
Q4 2020$4,000
-66.7%
2,262
-82.0%
0.00%
Q3 2020$12,000
+140.0%
12,544
+126.6%
0.00%
Q2 2020$5,000
-96.6%
5,536
-96.9%
0.00%
Q1 2020$148,000
+16.5%
178,846
+26.1%
0.00%
Q4 2019$127,000
+262.9%
141,846
+300.1%
0.00%
Q3 2019$35,00035,4560.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2020
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$41,223,8723.66%
Raffles Associates 1,587,739$1,873,5322.48%
Defender Capital, LLC. 5,184,510$6,117,7222.22%
Prescott General Partners LLC 1,851,851$2,185,1840.14%
DCF Advisers, LLC 82,751$97,6460.05%
Beirne Wealth Consulting Services, LLC 45,000$63,4500.05%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$922,4840.02%
Fort Sheridan Advisors LLC 83,931$99,0390.02%
MAI Capital Management 954,688$1,126,5320.02%
Piscataqua Savings Bank 12,499$14,6230.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders